Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report)’s stock price traded up 8.7% during trading on Friday. The company traded as high as $13.93 and last traded at $13.9150. 55,379 shares were traded during trading, a decline of 95% from the average daily volume of 1,062,721 shares. The stock had previously closed at $12.80.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on BAYRY. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 10th. Deutsche Bank Aktiengesellschaft upgraded Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy”.
Read Our Latest Analysis on BAYRY
Bayer Aktiengesellschaft Stock Up 4.9%
The company has a debt-to-equity ratio of 1.05, a current ratio of 1.04 and a quick ratio of 0.67. The firm has a market capitalization of $55.14 billion, a price-to-earnings ratio of -27.51, a price-to-earnings-growth ratio of 1.94 and a beta of 0.57. The firm’s 50-day moving average price is $13.43 and its 200 day moving average price is $12.52.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. The company had revenue of $12.53 billion during the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Sell-side analysts expect that Bayer Aktiengesellschaft will post 1.27 EPS for the current year.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.
Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, hematology and specialty therapies.
Featured Articles
- Five stocks we like better than Bayer Aktiengesellschaft
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.
